Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NVAX Novavax Inc
- Stocks
- Healthcare
- NASDAQ: NVAX
Price (delayed)
$5.96
Market cap
$965.34M
P/E Ratio
1.97
Dividend/share
N/A
EPS
$3.03
Enterprise value
$919.98M
Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III
Highlights
Novavax's EPS has surged by 197% YoY
NVAX's quick ratio has surged by 191% year-on-year and by 107% since the previous quarter
Key stats
What are the main financial stats of NVAX
Market
Valuations
Earnings
Shares outstanding
161.97M
Market cap
$965.34M
Enterprise value
$919.98M
Price to earnings (P/E)
1.97
Price to book (P/B)
N/A
Price to sales (P/S)
0.76
EV/EBIT
1.8
EV/EBITDA
1.66
EV/Sales
0.73
Revenue
$1.25B
Gross profit
$1.1B
Operating income
$411.41M
Net income
$478.7M
EBIT
$510.21M
EBITDA
$554.9M
Free cash flow
-$198.19M
Per share
Balance sheet
Liquidity
EPS
$3.03
EPS diluted
$3.03
Free cash flow per share
-$1.23
Book value per share
-$0.47
Revenue per share
$7.79
TBVPS
$7.33
Total assets
$1.29B
Total liabilities
$1.37B
Debt
$228.66M
Equity
-$75.64M
Working capital
$445.86M
Debt to equity
-3.02
Current ratio
2.06
Quick ratio
1.86
Net debt/EBITDA
-0.08
Margins
Efficiency
Dividend
EBITDA margin
44.2%
Gross margin
87.4%
Net margin
38.1%
Operating margin
32.8%
Return on assets
30%
Return on equity
N/A
Return on invested capital
244.3%
Return on capital employed
58.6%
Return on sales
40.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVAX stock price
How has the Novavax stock price performed over time
Intraday
-3.72%
1 week
0.17%
1 month
-7.02%
1 year
-55.79%
YTD
-25.87%
QTD
-7.02%
Financial performance
How have Novavax's revenue and profit performed over time
Revenue
$1.25B
Gross profit
$1.1B
Operating income
$411.41M
Net income
$478.7M
Gross margin
87.4%
Net margin
38.1%
Novavax's net margin has surged by 195% YoY
The operating margin has soared by 190% since the previous quarter and by 182% year-on-year
NVAX's gross profit has soared by 129% QoQ and by 75% YoY
The revenue has soared by 84% from the previous quarter and by 26% YoY
Price vs fundamentals
How does NVAX's price correlate with its fundamentals
Growth
What is Novavax's growth rate over time
Valuation
What is Novavax stock price valuation
P/E
1.97
P/B
N/A
P/S
0.76
EV/EBIT
1.8
EV/EBITDA
1.66
EV/Sales
0.73
Novavax's EPS has surged by 197% YoY
Novavax's equity has surged by 91% YoY and by 88% QoQ
NVAX's P/S is 93% below its 5-year quarterly average of 10.6 and 55% below its last 4 quarters average of 1.7
The revenue has soared by 84% from the previous quarter and by 26% YoY
Efficiency
How efficient is Novavax business performance
Dividends
What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVAX.
Financial health
How did Novavax financials performed over time
Novavax's total assets is 6% lower than its total liabilities
NVAX's quick ratio has surged by 191% year-on-year and by 107% since the previous quarter
The current ratio has surged by 129% year-on-year and by 110% since the previous quarter
Novavax's equity has surged by 91% YoY and by 88% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.